[{"data":1,"prerenderedAt":360},["ShallowReactive",2],{"content-\u002Faccess-samples\u002Freview-committee\u002Fme-cfs":3,"content-query-NLP0r8zX8P":242},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":7,"sidebar":9,"body":106,"_type":236,"_id":237,"_source":238,"_file":239,"_stem":240,"_extension":241},"\u002Faccess-samples\u002Freview-committee\u002Fme-cfs","review-committee",false,"","ME\u002FCFS BRAC",[10,62,69,72,79,100,103],{"title":11,"url":12,"children":13},"Available Samples","\u002Faccess-samples\u002Favailable-samples",[14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,59],{"title":15,"url":16},"2CARE","\u002Faccess-samples\u002Favailable-samples\u002F2care",{"title":18,"url":19},"ALL ALS","\u002Faccess-samples\u002Favailable-samples\u002Fallals",{"title":21,"url":22},"BioFIND","\u002Faccess-samples\u002Favailable-samples\u002Fbiofind",{"title":24,"url":25},"CFI","\u002Faccess-samples\u002Favailable-samples\u002Fcfi",{"title":27,"url":28},"CRC-SCA","\u002Faccess-samples\u002Favailable-samples\u002Fcrc-sca",{"title":30,"url":31},"ESFTLD","\u002Faccess-samples\u002Favailable-samples\u002Fesftld",{"title":33,"url":34},"GLIA-CTN","\u002Faccess-samples\u002Favailable-samples\u002Fglia-ctn",{"title":36,"url":37},"LETBI","\u002Faccess-samples\u002Favailable-samples\u002Fletbi",{"title":39,"url":40},"LBD\u002FDLB","\u002Faccess-samples\u002Favailable-samples\u002Flbd",{"title":42,"url":43},"MSA","\u002Faccess-samples\u002Favailable-samples\u002Fmsa",{"title":45,"url":46},"PDBP","\u002Faccess-samples\u002Favailable-samples\u002Fpdbp",{"title":48,"url":49},"PHD","\u002Faccess-samples\u002Favailable-samples\u002Fphd",{"title":51,"url":52},"PSP","\u002Faccess-samples\u002Favailable-samples\u002Fpsp",{"title":54,"url":55},"READISCA","\u002Faccess-samples\u002Favailable-samples\u002Freadisca",{"title":57,"url":58},"STEADY PD III","\u002Faccess-samples\u002Favailable-samples\u002Fsteady-pd3",{"title":60,"url":61},"SURE PD III","\u002Faccess-samples\u002Favailable-samples\u002Fsure-pd3",{"title":63,"url":64,"children":65},"Catalogs","\u002Faccess-samples\u002Fcatalogs",[66],{"title":67,"url":68},"Catalog Instructions","\u002Faccess-samples\u002Fcatalogs\u002Fcatalog-instructions",{"title":70,"url":71},"Reference Pools","\u002Faccess-samples\u002Freference-pools",{"title":73,"url":74,"children":75},"Request Samples","\u002Faccess-samples\u002Frequest-samples",[76],{"title":77,"url":78},"MTA for Receiving Samples","\u002Faccess-samples\u002Frequest-samples\u002Fmta-out",{"title":80,"url":81,"children":82},"Biospecimen Access Review Committees","\u002Faccess-samples\u002Freview-committee",[83,86,89,90,93,97],{"title":84,"url":85},"ALS BRAC","\u002Faccess-samples\u002Freview-committee\u002Fals",{"title":87,"url":88},"LD BRAC","\u002Faccess-samples\u002Freview-committee\u002Fld",{"title":8,"url":4},{"title":91,"url":92},"RED BRAC","\u002Faccess-samples\u002Freview-committee\u002Fred",{"title":94,"url":95,"external":96},"PD BRAC","https:\u002F\u002Fpdbp.ninds.nih.gov\u002Fpd-brac",true,{"title":98,"url":99,"external":96},"TBI BRAC","https:\u002F\u002Ffitbir.nih.gov\u002Fninds-tbi-brac",{"title":101,"url":102},"Publications","\u002Faccess-samples\u002Fpublications",{"title":104,"url":105},"Grant Acknowledgement","\u002Faccess-samples\u002Facknowledgement",{"type":107,"children":108,"toc":233},"root",[109],{"type":110,"tag":111,"props":112,"children":113},"element","layout-wrapper",{},[114,120],{"type":110,"tag":115,"props":116,"children":119},"sidebar",{":nav-items":115,"className":117,"sidebar-title":8},[118],"section-nav-dktp",[],{"type":110,"tag":121,"props":122,"children":124},"layout-content",{":custom-breadcrumbs":123},"[{\"path\":\"\u002Faccess-samples\",\"name\":\"Access Samples\"},{\"path\":\"\u002Faccess-samples\u002Freview-committee\",\"name\":\"Review Committee\"},{\"path\":\"\u002Faccess-samples\u002Freview-committee\u002Fme-cfs\",\"name\":\"ME\u002FCFS\"}]",[125,131,140,147,156,164,169,191,193,198,218],{"type":110,"tag":126,"props":127,"children":130},"header-block-one",{"className":128,"title":8},[129],"rvt-m-bottom-none",[],{"type":110,"tag":132,"props":133,"children":139},"heading",{"className":134,"level":137,"text":138},[135,136],"ncrad-blue","rvt-m-top-sm","2","Myalgic Encephalomyelitis \u002F Chronic Fatigue Syndrome Biospecimen Review Access Committee",[],{"type":110,"tag":141,"props":142,"children":143},"p",{},[144],{"type":145,"value":146},"text","The Myalgic Encephalomyelitis \u002F Chronic Fatigue Syndrome Biospecimen Review Access Committee (ME\u002FCFS BRAC) reviews applications for samples from studies of ME\u002FCFS.",{"type":110,"tag":148,"props":149,"children":155},"rvt-table",{":headers":150,":rows":151,"className":152,"title":154},"[\"Date Submitted\",\"Reviewed by\"]","[[\"October 17, 2025 - December 21, 2025\",\"January 21, 2026\"],[\"December 22, 2026 - February 12, 2026\",\"March 18, 2026\"],[\"February 13, 2026 - April 16, 2026\",\"May 20, 2026\"],[\"April 17, 2026 - June 11, 2026\",\"July 15, 2026\"],[\"June 12, 2026 - August 13, 2026\",\"September 16, 2026\"],[\"August 14, 2026 - October 15, 2026\",\"November 18, 2026\"],[\"October 16, 2026 - December 17, 2026\",\"January 20, 2027\"]]",[153],"rvt-bottom-lg","Submission and Review Dates ",[],{"type":110,"tag":157,"props":158,"children":163},"accordion",{":accordions":159,"className":160},"[{\"title\":\"Review Process\",\"content\":\"\u003Cp>The BRAC committee will assess the applications based on experimental rationale, feasibility\u002Freproducibility of the assays, expertise of the investigator, availability of the institutional resources to support the study, and the statistical analysis of the number of samples required for the hypothesis testing.  Investigators will be notified by email the outcome of the review (i.e. approve, approve upon revisions, or deny) within a week after the review meeting.  Summary statements are released 2-3 weeks after review.  For applications that were ‘approved upon revisions’, investigators will be notified about concerns that would need to be addressed before the application could move forward.  Please note that the ME\u002FCFS BRAC does not provide funding.  \u003C\u002Fp>\\n\\n\u003Cp>If sample access is approved by the ME\u002FCFS BRAC, the two possible outcomes are: \u003C\u002Fp>\\n\\n\u003Col>\\n  \u003Cli>If the study has funding, the samples are distributed to the investigator following a virtual meeting to introduce the sample distribution process (“on-boarding”) and after fulfilment by the investigator of additional requirements specified by BioSEND (i.e. MTA, Data Use Agreement, data analysis and sharing plan).  For questions, please contact \u003Ca href=\\\"mailto:NINDS-HD-BRAC@ninds.nih.gov\\\">Rebecca Price, Ph.D.\u003C\u002Fa>\u003C\u002Fli> \\n\\n  \u003Cli>If the investigator has yet to obtain funding for the study, the BRAC will issue a letter to the applicant documenting provisional access to the samples requested.  This letter can be used to support an application for funding opportunities from the NIH or other organizations.  Conditional approvals will be valid for a period of up to 12 months.\u003C\u002Fli>\\n\u003C\u002Fol>\\n\\n\u003Cp>To facilitate scientific rigor and reproducibility, samples for approved applications are shipped blinded (each aliquot is labeled with a Sample ID). The BioSEND team will work with investigators during the onboarding call to create box designs to facilitate blinded analyses. Investigators must return their assay analyses into an appropriate data repository prior to being unblinded by BioSEND.\u003C\u002Fp>\\n\"}]",[161,162],"samples-accordions","als-brac",[],{"type":110,"tag":157,"props":165,"children":168},{":accordions":166,"className":167},"[{\"title\":\"ME\u002FCFS BRAC Membership\",\"content\":\"\u003Caddress>\\n  \u003Cstrong>Alaedini, Armin, PhD\u003C\u002Fstrong>\u003Cbr\u002F>\\n  Assistant Professor of Medicine\u003Cbr\u002F>\\n  Columbia University Medical Center\u003Cbr\u002F>\\n  New York, NY 10032\u003Cbr\u002F>\\n\u003C\u002Faddress>\\n\\n\u003Caddress>\\n  \u003Cstrong>Chen, Yang, DrPH\u003C\u002Fstrong>\u003Cbr\u002F>\\n  Epidemiologist\u003Cbr\u002F>\\n  Centers for Disease Control and Prevention\u003Cbr\u002F>\\n  Atlanta, GA 30333\u003Cbr\u002F>\\n\u003C\u002Faddress>\\n\\n\u003Caddress>\\n        \u003Cstrong>Franconi, Carl, MS\u003C\u002Fstrong>\u003Cbr\u002F>\\n        Manager\u003Cbr\u002F>\\n        Center for Enervating Neuroimmune Disease, Cornell University\u003Cbr\u002F>\\n        Ithaca, NY 14850\u003Cbr\u002F>\\n      \u003C\u002Faddress>\\n\\n\u003Caddress>\\n        \u003Cstrong>Grimson, Andrew, PhD\u003C\u002Fstrong>\u003Cbr\u002F>\\n        Professor, Molecular Biology and Genetics\u003Cbr\u002F>\\n        Cornell University\u003Cbr\u002F>\\n        Ithaca, NY 14850\u003Cbr\u002F>\\n      \u003C\u002Faddress>\\n\\n\u003Caddress>\\n        \u003Cstrong>Hsiao, H Timothy, PhD\u003C\u002Fstrong>\u003Cbr\u002F>\\n        Chief Scientific Officer, Head of Research Strategy & Alliances\u003Cbr\u002F>\\n        Solve M.E.\u003Cbr\u002F>\\n        Glendale, CA 91206\u003Cbr\u002F>\\n      \u003C\u002Faddress>\\n\\n\u003Caddress>\\n        \u003Cstrong>Klimas, Nancy, MD\u003C\u002Fstrong>\u003Cbr\u002F>\\n        Director, Institute for Neuro-Immune Medicine\u003Cbr\u002F>\\n        Nova Southeastern University\u003Cbr\u002F>\\n        Fort Lauderdale, FL 33328\u003Cbr\u002F>\\n      \u003C\u002Faddress>\\n\\n\u003Caddress>\\n        \u003Cstrong>Nacul, Luis, MBBS, PhD\u003C\u002Fstrong>\u003Cbr\u002F>\\n        Clinical Associate Professor\u003Cbr\u002F>\\n        London School of Hygiene and Tropical Medicine\u003Cbr\u002F>\\n        London, United Kingdom\u003Cbr\u002F>\\n      \u003C\u002Faddress>\\n\\n\u003Caddress>\\n        \u003Cstrong>Mangalathu Rajeevan, PhD\u003C\u002Fstrong>\u003Cbr\u002F>\\n        Microbiologist\u003Cbr\u002F>\\n        Centers for Disease Control and Prevention\u003Cbr\u002F>\\n        Atlanta, GA 30333\u003Cbr\u002F>\\n      \u003C\u002Faddress>\\n\\n\u003Caddress>\\n        \u003Cstrong>Unger, Elizabeth, MD\u003C\u002Fstrong>\u003Cbr\u002F>\\n        Chief, Chronic Viral Diseases Branch, Centers for Disease Control and Prevention\u003Cbr\u002F>\\n        Atlanta, GA 30333\u003Cbr\u002F>\\n      \u003C\u002Faddress>\\n\"}]",[161,162],[],{"type":110,"tag":141,"props":170,"children":172},{"className":171},[129],[173],{"type":110,"tag":174,"props":175,"children":176},"em",{},[177,179,189],{"type":145,"value":178},"Please note that your application will be shared with BRAC members, NINDS program staff, and BioSEND staff. Access and review of all applications is guided ethical research standards, as described in the ",{"type":110,"tag":180,"props":181,"children":186},"a",{"href":182,"className":183,"target":185},"\u002Fassets\u002Faccess-samples\u002FBRAC Confidentiality agreement 2024_508C.pdf",[184],"link","_blank",[187],{"type":145,"value":188},"Confidentiality Agreement",{"type":145,"value":190},".",{"type":145,"value":192},"  ",{"type":110,"tag":157,"props":194,"children":197},{":accordions":195,"className":196},"[{\"title\":\"Previously Approved Applications \",\"content\":\"\u003Ch3>Cellular Circadian Rhythm Disruption in ME\u002FCFS \u003C\u002Fh3>\\n\u003Cp>Michael McCarthy, University of California – San Diego\u002FVA San Diego Healthcare Research Service \u003C\u002Fp>\\n\u003Cp class=\\\"rvt-m-all-none\\\">Cohort: Chronic Fatigue Initiative (CFI) \u003Cbr\u002F> Review Date: 2021 \u003C\u002Fp>\\n\\n\u003Cp>Abstract: We hypothesize that TGF-β signaling is upregulated in ME\u002FCFS and remains persistently elevated leading to a series of pathological events including circadian rhythm disruption that contributes to sleep disruption and cognitive complaints in a subset of ME\u002FCFS patients. We anticipate that serum from ME\u002FCFS patients with significant sleep disruption will be sufficient to cause circadian disruption in cultured fibroblasts and neurons. Our laboratory has substantial experience performing cellular circadian rhythm assays and has extensively used the NIH 3T3 cell model with Per2-luc transfection. In this aim, the effects on rhythms of serum from ME\u002FCFS patients and control will be studied using Per2-luc in fibroblasts to determine if there are disease-specific factors (such as TGF-β) that affect cellular rhythms in live cells. In multi-day cellular rhythm assays using live cells, we will identify and characterize ME\u002FCFS-associated abnormalities, identify the serum factors responsible, and assess the role of TGF-β using gene expression knockdown, recombinant cytokines, and pharmacological interventions to recapitulate or block the effects of serum. \u003C\u002Fp>\\n\\n\u003Ch3>Autoantibodies Against Chemokines in CFS\u002FME \u003C\u002Fh3>\\n\u003Cp>Davide Robbiani, Università della Svizzera italiana  \u003C\u002Fp>\\n\u003Cp class=\\\"rvt-m-all-none\\\">Cohort: Chronic Fatigue Initiative (CFI)  \u003Cbr\u002F>Review Date: Pilot analysis, 2022; Expanded analysis 2023 \u003C\u002Fp>\\n\\n\u003Cp>Abstract: The primary aim of this pilot study is to measure the level of plasma autoantibodies against the 43 human chemokines in CFS\u002FME patients. This will be compared to matched cohort controls, and to convalescent individuals after COVID-19 (with or without long-COVID) and other infections. Moreover, as a secondary aim, we will test the hypothesis that common cold coronaviruses may be involved in CFS\u002FME pathogenesis by measuring the same samples for the presence of antibodies to the spike protein of human common cold coronaviruses (229E, OC43, NL63, HKU1) and SARS-CoV-2. Since the presence of specific anti-chemokine antibodies is associated with protection from long-COVID, in addition to having diagnostic utility, the study of these autoantibodies in CFS\u002FME has the potential to pave the way to novel therapeutic approaches.\u003C\u002Fp>\\n\\n\u003Ch3>Sluss MECFS NINDS Research Strategy\u003C\u002Fh3>\\n\u003Cp>Hayla Sluss, University of Massachusetts Chan Medical School\u003C\u002Fp>\\n\u003Cp class=\\\"rvt-m-all-none\\\">Cohort: Chronic Fatigue Initiative (CFI)  \u003Cbr\u002F>Review Date: 2024 \u003C\u002Fp>\\n\\n\u003Cp>Abstract: A correlate of ME\u002FCFS disease is the presence of vascular endothelial cell dysfunction that may contribute to pathogenesis. Endothelial cell dysfunction in ME\u002FCFS has been characterized by decreased eNOS activity and production of nitric oxide (NO), endothelial cell senescence, and increased permeability of the intestinal and blood brain barrier that lead to endotoxin-mediated inflammation. This dysfunction has been proposed to be mediated by changes in the serum proteome and metabolome. Evidence to support this conclusion is based on the effects of ME\u002FCFS serum to suppress NO production by endothelial cells. Moreover, ME\u002FCFS plasma, compared with control plasma, promotes endothelial cell senescence. Endothelial dysfunction can lead to impaired blood brain barrier function. In addition, ME\u002FCFS disease is associated with mitochondrial defects that may contribute to disease pathogenesis. This study aims to shed light on the role of endothelial senescence in ME\u002FCFS pathogenesis. Understanding these mechanisms will have important translational implications for developing targeted interventions to improve outcomes in ME\u002FCFS patients. \u003C\u002Fp>\\n\\n\"}]",[162],[],{"type":110,"tag":141,"props":199,"children":200},{},[201,208,212],{"type":110,"tag":180,"props":202,"children":205},{"href":74,"className":203},[204],"rvt-cta",[206],{"type":145,"value":207},"Learn more about the review process",{"type":110,"tag":209,"props":210,"children":211},"br",{},[],{"type":110,"tag":180,"props":213,"children":215},{"href":12,"target":185,"className":214},[204],[216],{"type":145,"value":217},"View available samples",{"type":110,"tag":141,"props":219,"children":220},{},[221],{"type":110,"tag":180,"props":222,"children":230},{"className":223,"id":228,"href":229,"target":185},[224,225,226,227],"rvt-button","rvt-button--primary-btn","rvt-m-right-md","rvt-justify-center","height-2-5","\u002Fbrac_application",[231],{"type":145,"value":232},"Submit Application",{"title":7,"searchDepth":234,"depth":234,"links":235},2,[],"markdown","content:access-samples:review-committee:me-cfs.md","content","access-samples\u002Freview-committee\u002Fme-cfs.md","access-samples\u002Freview-committee\u002Fme-cfs","md",{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":7,"sidebar":243,"body":279,"_type":236,"_id":237,"_source":238,"_file":239,"_stem":240,"_extension":241},[244,262,265,266,269,277,278],{"title":11,"url":12,"children":245},[246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261],{"title":15,"url":16},{"title":18,"url":19},{"title":21,"url":22},{"title":24,"url":25},{"title":27,"url":28},{"title":30,"url":31},{"title":33,"url":34},{"title":36,"url":37},{"title":39,"url":40},{"title":42,"url":43},{"title":45,"url":46},{"title":48,"url":49},{"title":51,"url":52},{"title":54,"url":55},{"title":57,"url":58},{"title":60,"url":61},{"title":63,"url":64,"children":263},[264],{"title":67,"url":68},{"title":70,"url":71},{"title":73,"url":74,"children":267},[268],{"title":77,"url":78},{"title":80,"url":81,"children":270},[271,272,273,274,275,276],{"title":84,"url":85},{"title":87,"url":88},{"title":8,"url":4},{"title":91,"url":92},{"title":94,"url":95,"external":96},{"title":98,"url":99,"external":96},{"title":101,"url":102},{"title":104,"url":105},{"type":107,"children":280,"toc":358},[281],{"type":110,"tag":111,"props":282,"children":283},{},[284,288],{"type":110,"tag":115,"props":285,"children":287},{":nav-items":115,"className":286,"sidebar-title":8},[118],[],{"type":110,"tag":121,"props":289,"children":290},{":custom-breadcrumbs":123},[291,295,299,303,307,311,315,329,330,334,350],{"type":110,"tag":126,"props":292,"children":294},{"className":293,"title":8},[129],[],{"type":110,"tag":132,"props":296,"children":298},{"className":297,"level":137,"text":138},[135,136],[],{"type":110,"tag":141,"props":300,"children":301},{},[302],{"type":145,"value":146},{"type":110,"tag":148,"props":304,"children":306},{":headers":150,":rows":151,"className":305,"title":154},[153],[],{"type":110,"tag":157,"props":308,"children":310},{":accordions":159,"className":309},[161,162],[],{"type":110,"tag":157,"props":312,"children":314},{":accordions":166,"className":313},[161,162],[],{"type":110,"tag":141,"props":316,"children":318},{"className":317},[129],[319],{"type":110,"tag":174,"props":320,"children":321},{},[322,323,328],{"type":145,"value":178},{"type":110,"tag":180,"props":324,"children":326},{"href":182,"className":325,"target":185},[184],[327],{"type":145,"value":188},{"type":145,"value":190},{"type":145,"value":192},{"type":110,"tag":157,"props":331,"children":333},{":accordions":195,"className":332},[162],[],{"type":110,"tag":141,"props":335,"children":336},{},[337,342,345],{"type":110,"tag":180,"props":338,"children":340},{"href":74,"className":339},[204],[341],{"type":145,"value":207},{"type":110,"tag":209,"props":343,"children":344},{},[],{"type":110,"tag":180,"props":346,"children":348},{"href":12,"target":185,"className":347},[204],[349],{"type":145,"value":217},{"type":110,"tag":141,"props":351,"children":352},{},[353],{"type":110,"tag":180,"props":354,"children":356},{"className":355,"id":228,"href":229,"target":185},[224,225,226,227],[357],{"type":145,"value":232},{"title":7,"searchDepth":234,"depth":234,"links":359},[],1776435642218]